Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Sparrow Pharmaceuticals, Inc.
What AI says about Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering targeted therapies for patients with type 2 diabetes, particularly those affected by elevated cortisol levels. Their lead candidate, clofutriben, aims to improve glycemic control and metabolic health for underserved patients.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
Clofutriben
A novel HSD-1 inhibitor designed to reduce elevated intracellular cortisol levels in patients with type 2 diabetes.
Common Questions
What is Sparrow Pharmaceuticals focused on?
Sparrow Pharmaceuticals is focused on developing targeted therapies for cardiometabolic diseases, specifically for patients with type 2 diabetes.
What is clofutriben?
Clofutriben is a highly potent and selective HSD-1 inhibitor in development for the treatment of type 2 diabetes with elevated cortisol.
Who can benefit from Sparrow's therapies?
Patients with type 2 diabetes who have difficulty controlling their blood sugar levels and are underserved by existing treatment options can benefit from Sparrow's therapies.
What clinical trials is Sparrow Pharmaceuticals conducting?
Sparrow Pharmaceuticals is conducting the CAPTAIN-T2D Phase 2b clinical trial to evaluate clofutriben for treatment-resistant type 2 diabetes.
What is the mechanism of action of clofutriben?
Clofutriben works by inhibiting HSD-1 to lower intracellular cortisol levels, which can help mitigate the adverse metabolic effects caused by excess cortisol.